Meiogenix SAS

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Meiogenix SAS - overview

Established

2010

Location

Paris, -, France

Primary Industry

Biotechnology

About

Meiogenix SAS is an agricultural biotechnology company dedicated to enhancing crop genetic diversity through innovative Chromosome Editing techniques, aimed at addressing climate change and food security challenges. Founded in 2010 and headquartered in Paris, France, Meiogenix SAS specializes in agricultural biotechnology, focusing on enhancing crop genetic diversity. The company has completed 4 deals, with the most recent deal dated August 18, 2022, when it raised EUR 5. 5 million in a funding round led by Sofinnova Partners.


The current CEO is Luc Mathis, who has played a pivotal role in guiding the company's strategic direction. Meiogenix specializes in innovative agricultural biotechnology, focusing on Chromosome Editing to enhance crop genetic diversity. Their core offerings aim to unlock unexplored genetic traits in crops, thereby creating novel natural varieties tailored to meet the challenges of climate change, sustainability, and food security. These products are designed for farmers seeking solutions to improve crop resilience and yield without relying on traditional genetic modification techniques.


The primary end-users of these technologies include agricultural producers and farming cooperatives that operate in diverse geographical markets, including North America, Europe, and parts of Asia, where there is a growing demand for sustainable agricultural practices. In the most recent year, Meiogenix reported revenue of EUR 1,867,600 and an EBITDA of EUR 853,639. The company generates revenue through strategic partnerships and collaborations with agricultural producers and research institutions, licensing its Chromosome Editing technologies on a B2B basis. Revenue structures include milestone payments and royalties based on the commercial success of crop varieties developed through these partnerships.


Following the EUR 5. 5 million funding round in August 2022, Meiogenix plans to utilize these funds to support the development of new products focused on enhancing crop resilience. The company is also targeting expansion into additional markets in Asia and North America by 2024, aiming to address the increasing demand for sustainable agricultural solutions. This growth strategy is designed to foster long-term partnerships that align with their mission to enhance agricultural sustainability and biodiversity.


Current Investors

Sofinnova Partners, Alexandria Venture Investments, Casdin Capital

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy

Website

www.meiogenix.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Meiogenix SAS - financials

Fiscal Year EndedDec 31, 2016Dec 31, 2017Dec 31, 2018Dec 31, 2019
Revenue (USD)68,500---
% Revenue Growth (YoY)----
EBITDA (USD)(704,869)---
Operating Income (USD)(742,301)---
Operating Margin(1083.7%)---
% EBITDA Margin(1029.0%)---
NET Income (USD)(443,961)---
% Net Margin(648.1%)---

Meiogenix SAS - employee data

Blurred Background

Want to see Employee Count?

Request a demo for full access to this profile.

Meiogenix SAS - key contacts

NamePositionStart DateEnd DateVcardBio 
Board DirectorBM
Chairman Of The BoardBM

BM Board Member

Want to see more?

Request a demo for full access to this profile

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.